Clinical Trial Update: Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating the combination of venetoclax and acalabrutinib for relapsed or refractory mantle cell lymphoma, including various MCL …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• Venclexta (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression | Phase 2 | Status: ACTIVE_NOT_RECRUITING